ROTATE

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) (ROTATE)

What's the purpose of the trial?

In this study, participants who are MRD positive after front line therapy will receive consolidation with GPRC5D-targeted bispecific talquetamab.

Trial status

Accepting patients

Phase
Phase 2
Enrollment
50
Last Updated

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Teclistamab is a bispecific antibody that targets BCMA, which is expressed in mature B lymphocytes, and CD3, which is expressed on T-cells.
  • Talquetamab is a bispecific antibody that binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. 

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Arm 1

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.